Business Context and Reporting Period
This Form 8-K filing by DaVita Inc. (DVA) was submitted on September 9, 2024, reporting a corporate governance event. The filing details the appointment of a new Chief Operating Officer for DaVita Kidney Care and the transition of the incumbent to an emeritus role.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- Base Salary (New COO): $725,000 annually.
- Target Incentive Bonus: 100% of base salary for 2024.
- Severance Terms: Eligible for benefits under the DaVita Inc. Severance Plan upon termination without cause or resignation for good cause.
Material Changes
The primary material change is the leadership transition within DaVita Kidney Care:
- Appointment: David P. Maughan, previously Senior Vice President, was appointed Chief Operating Officer, effective September 15, 2024.
- Departure: Michael D. Staffieri is transitioning to the role of Chief Operating Officer Emeritus as of the same effective date.
- Background: Mr. Maughan has been with DaVita since 2006, most recently overseeing national home and hospital services, human resources, IT, and government affairs.
Outlook, Risks, and Unusual Items
The filing outlines specific contractual protections for the new executive rather than providing strategic outlook or risk factors:
- Termination Benefits: If terminated without cause, Mr. Maughan receives Severance Plan benefits. If he resigns for good cause, he is entitled to at least one year of base salary continuation (two years if within 60 days of a change in control event occurring within two years).
- Pro-Rated Bonus: In the event of termination after April in a given year, a pro-rated lump-sum bonus based on the prior year's payment is provided.
- Conditions: All severance benefits are subject to the execution of a release and continued cooperation.
Investor Verification Checklist
- Verify the effective date of the leadership transition (September 15, 2024).
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "material cause" and "good cause."
- Confirm the terms of the DaVita Inc. Severance Plan referenced in the agreement.
- Monitor subsequent filings for any impact of this leadership change on operational strategy or financial guidance.